Adoptive cell therapy (ACT) with tumor-reactive lymphocytes in patients with refractory
melanoma can result in tumor regression and prolonged survival. Generating tumor-reactive
lymphocyte cultures is technically difficult and resource intensive; these limitations have
restricted the widespread application of ACT. Tumor-infiltrating lymphocytes (TIL) from
melanoma contain tumor antigen-reactive cells. The “standard” method for producing TIL
cultures for clinical administration requires extended in vitro expansion in interleukin-2, then …